This is the first study to collect real-world WATCHMAN LAA Closure Device experience outside of selected populations in randomized trials.

Results from the prospective, multi-centre EWOLUTION registry include:

• The lowest peri-procedural risk of any WATCHMAN trial, even in multi-morbid patients with high stroke and bleeding risk. There was only a 2.8 percent procedure-related serious adverse event (SAE) rate at seven days post implant.
• The highest risk patient population ever studied in a WATCHMAN trial. Baseline data showed higher CHADS2 (2.8 ± 1.3), CHA2DS2-VASc (4.5 ± 1.6) and HAS-BLED (2.3 ± 1.2) scores compared to prior WATCHMAN trials.

                - 61.8 percent of patients were deemed to be                 contraindicated for oral anticoagulation.

• Patients will continue be followed for two years to obtain data on long-term patient outcomes, including bleeding and incidence of stroke and transient ischemic attack.